Methods for Treating, Preventing, Inhibiting, or Reducing Cytokine Release
Oxathiazine-like compounds like C-2250 are administered to inhibit cytokine release in CRS and cytokine storm, addressing the limitations of current treatments by effectively reducing symptoms without impairing cancer therapy efficacy.
Patent Information
- Application Number
- JP2021568994
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-05-22
- Filing Date
- 2020-05-21
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2040-05-21
AI Technical Summary
Current treatments for cytokine release syndrome (CRS) and cytokine storm, such as corticosteroids and anti-IL6 therapies, are inadequate as they can reduce the effectiveness of cancer immunotherapies and have limited efficacy in suppressing a wide range of cytokines, posing a significant risk to patients.
Administering compositions that increase blood levels of specific cytokines to inhibit or reduce cytokine release, including methods to treat CRS or cytokine storm, without impairing the cytotoxicity of anti-cancer therapeutics, using oxathiazine-like compounds like C-2250 to target multiple cytokines.
The approach effectively inhibits cytokine release and reduces symptoms of CRS or cytokine storm, while maintaining the effectiveness of cancer immunotherapies by not impairing the killing of cancer cells, thus providing a safer and more comprehensive treatment.
Smart Images

Figure 0007588603000006 
Figure 0007588603000007 
Figure 0007588603000008
Abstract
Description
[Technical field]
[0001] The present disclosure relates to compositions and methods for treating, inhibiting, preventing, or reducing cytokine release, cytokine release syndrome (CRS), or cytokine storm in a subject. [Background technology]
[0002] Cytokines are small secreted proteins required for immune cell signaling, activation, and recruitment of other inflammatory cells. Cytokines can be secreted by various types of cells in response to various pathologies, diseases, disorders, treatments, and agents. Cytokines are small secreted proteins released by cells that have specific effects on cell-cell interactions and communication. Cytokines is a general term, other names include lymphokines (cytokines made by lymphocytes), monokines (cytokines made by monocytes), chemokines (cytokines with chemotactic activity), and interleukins (cytokines made by some white blood cells that act on other white blood cells). Cytokines can act on the cell that secretes them (autocrine action), on nearby cells (paracrine action), or in some cases on distant cells (endocrine action). There are both pro-inflammatory and anti-inflammatory cytokines. Certain cytokines / chemokines are involved in various diseases, disorders, and pathologies.
[0003] Cytokine release syndrome (CRS) is a systemic inflammatory response that can be triggered by a variety of factors, including infections and certain drugs. Cancer immunotherapy can include adoptive transfer of T cells with chimeric antigen receptors (CARs) that target cancer cells (e.g., B cells with the antigen CD19 in B cell leukemia), bispecific antibodies that target cancer cells (e.g., BlinCyto, which links CD3 on T cells with CD19 on B cells for the treatment of B cell leukemia), or high doses of IL2 (e.g., for the treatment of melanoma). These immunotherapies are often associated with short-term or potentially life-threatening CRS as well as neurotoxicity. CRS results from activation of myeloid cells by activated T cells. CRS was seen when the anti-T cell antibody muromonab-CD3 (OKT3) was introduced into the clinic as an immunosuppressive treatment for solid organ transplantation. Subsequently, CRS has been reported after infusion of several antibody-based therapeutic agents, such as antithymocyte globulin (ATG), CD28 superagonist TGN1412, rituximab, obinutuzumab, alemtuzumab, brentuximab, dacetuzumab, and nivolumab. CRS has also been seen after administration of non-protein-based anticancer drugs, such as oxaliplatin and lenalidomide. Furthermore, CRS has been reported in the setting of haploidentical donor stem cell transplantation and graft-versus-host disease.
[0004] The standard treatments for cancer are surgery, chemotherapy, and radiation therapy, but improved methods such as targeted immunotherapy are now being developed and tested. One promising technique uses adoptive cell transfer (ACT), in which immune cells are modified to recognize and attack tumors. One example of ACT is when the patient's own T cells or donor's T cells are genetically engineered to express chimeric antigen receptors (e.g., CAR T cells) that target tumor-specific antigens expressed on the surface of tumor cells. These CAR T cells then exhibit cytotoxicity only against cells expressing the tumor-specific antigen. With the success of newer T cell-guided immunotherapeutic agents, interest in CRS has increased, as it is one of the most frequent and severe adverse effects of these therapeutic agents. T cell-guided immunotherapeutic agents include bispecific antibody constructs and chimeric antigen receptor (CAR) T cell therapeutic agents. Recently, both of these immunotherapeutic strategies have progressed to clinical application and have shown impressive therapeutic activity in several hematological malignancies, such as acute lymphoblastic B-cell leukemia (B-ALL), chronic lymphocytic leukemia (CLL), and diffuse large B-cell lymphoma (DLBCL).
[0005] Recently, the two first CAR T cell therapies, tisagenlecleucel and axicabtagene ciloleucel, received FDA approval for refractory CD19-positive B-ALL and relapsed or refractory large B-cell lymphoma. Numerous other bispecific antibodies and CAR T cell constructs targeting various antigens are currently in clinical development. In addition, there are several related T cell-guided and other immune cell immunotherapy approaches in early clinical development. These immunotherapy approaches include dual-affinity re-targeting antibodies (DART), immune mobilizing monoclonal T cell receptor (TCR) against cancer (ImmTAC), and other TCR-based strategies.
[0006] Studies of the first T cell-directed therapies, namely blinatumomab and CD19-targeted CAR T cells, revealed that CRS is a serious adverse event of these therapies. Thus, most of the current CRS data comes from studies of CAR T cells and blinatumomab in hematological malignancies, where CRS has been reported with a frequency of up to 100% in CD19-targeted CAR T cell trials, sometimes with fatal outcomes. In CRS, infused activated T cells induce a systemic inflammatory response, with a rapid and massive release of cytokines into the bloodstream, causing dangerously low blood pressure, high fever, and shivering.
[0007] In severe cases of CRS, patients experience a "cytokine storm" (also known as a cytokine cascade or hypercytokinemia) in which a positive feedback loop between cytokines and white blood cells leads to greatly elevated cytokine levels, which can lead to potentially life-threatening complications including cardiac dysfunction, adult respiratory distress syndrome, neurotoxicity, renal and / or hepatic failure, pulmonary edema, and disseminated intravascular coagulation.
[0008] Cytokine storms are also a problem following other infectious and non-infectious stimuli.
[0009] CRS or cytokine storm releases a number of proinflammatory cytokines, such as interleukin-1 (IL-1), IL-6, gamma interferon (g-IFN, IFN-g, or IFN-γ), and tumor necrosis factor alpha (TNFα), resulting in hypotension, hemorrhage, and ultimately multiple organ failure. Symptoms caused by cytokine storm range from rash or fever to neurotoxicity. This syndrome is also known to occur in advanced or end-stage cases of many other infectious diseases, including severe acute respiratory syndrome (SARS), Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis, gram-negative sepsis, influenza, malaria, and Ebola infection. Cytokine release, cytokine storm, or CRS can also result from non-infectious causes, such as acute pancreatitis, severe burns or trauma, or acute respiratory distress syndrome.
[0010] To date, corticosteroids, biological therapies such as anti-IL6 therapy, and anti-inflammatory drugs have been evaluated to suppress cytokine release syndrome and cytokine storm in patients who have been administered immunotherapy drugs such as CAR T cell therapy. However, such agents have typically been found to negatively affect response rates to T cell-guided therapy, ultimately leading to relapse. Steroids can affect the activity and / or proliferation of CAR T cells, putting patients at risk for sepsis and opportunistic infections. Anti-inflammatory drugs may not be effective in suppressing cytokine release syndrome or cytokine storm, because cytokine storm involves a large number of cytokines, while the ability to infuse anti-inflammatory drugs into patients is limited.
[0011] The FDA has expanded the indications for tocilizumab (ACTEMRA™) from its original designation for the treatment of rheumatoid arthritis (RA) to include the treatment of CRS in patients undergoing CAR T therapy. Tocilizumab works by blocking the interleukin-6 (IL-6) receptor, a proinflammatory cytokine, but does not inhibit cytokine release. Thus, while tocilizumab provides some symptomatic relief in some subjects, there is much room for improvement. The approval of tocilizumab for the treatment of severe or life-threatening CAR T cell-induced CRS in adult and pediatric patients aged 2 years and older was based on a retrospective data analysis in two cohorts showing response rates of 53% to 69%. The FDA approval for tocilizumab was supported solely by literature review. Furthermore, tocilizumab is a monoclonal antibody against a single cytokine receptor, IL6, however, CRS and cytokine storm involve multiple cytokines in addition to IL-6, including but not limited to TNF-α, interferon gamma, interleukins such as IL-1β, IL-2, IL-8, and IL-10. Summary of the Invention [Problem to be solved by the invention]
[0012] Thus, there is a long felt and unmet need for new compositions and methods for treating, inhibiting, suppressing, reducing and preventing cytokine release, including conditions such as cytokine release syndrome and cytokine storm. There is a long felt and unmet need for broad spectrum cytokine release inhibitors, particularly cytokine release inhibitors that do not reduce the cytotoxicity of anti-cancer therapeutics to target tumor cells. [Means for solving the problem]
[0013] In one aspect, the present disclosure provides a method of treating, preventing, inhibiting, or reducing increased blood levels of one or more cytokines in a subject in need thereof by administering to the subject a composition of the present disclosure.
[0014] In one aspect, the present disclosure provides a method of treating, preventing, inhibiting, or reducing the occurrence of cytokine release syndrome (CRS) or cytokine storm in a subject by administering to the subject a composition of the present disclosure.
[0015] In one aspect, the disclosure provides a method of treating, preventing, inhibiting, or reducing the neurotoxicity of a CAR T cell therapy, antibody therapy, or bispecific antibody therapy in a subject by administering to the subject a composition of the disclosure.
[0016] In one aspect, the present disclosure provides a method of treating, preventing, reducing, or inhibiting cytokine production in a subject experiencing or susceptible to cytokine release syndrome or cytokine storm by administering to the subject a composition of the present disclosure.
[0017] In one aspect, the present disclosure provides a method of treating one or more symptoms or adverse reactions caused by an infectious disease or a condition that causes widespread release of cytokines in a subject by administering to the subject a composition of the present disclosure.
[0018] In one aspect, the disclosure provides a method of increasing the maximum tolerated dose of a T cell-directed immunotherapeutic administered to a subject by administering to the subject a composition of the disclosure.
[0019] In one aspect, the disclosure provides a method of treating, inhibiting, preventing, or treating vascular leakage in a subject in need thereof by administering to the subject a composition of the disclosure.
[0020] In one aspect, the present disclosure provides a method of treating cardiomyopathy and / or myocardial dysfunction in a subject at risk for cardiomyopathy and / or myocardial dysfunction due to cytokine release, cytokine release syndrome, or cytokine storm by administering to the subject a composition of the present disclosure.
[0021] In some embodiments, the cause of cytokine release, cytokine release syndrome, or cytokine storm can include an infectious stimulus, infectious condition, or infectious syndrome. In some embodiments, the cause of cytokine release, cytokine release syndrome, or cytokine storm can include a non-infectious stimulus, non-infectious condition, or non-infectious syndrome. In some embodiments, the cause of cytokine release, cytokine release syndrome, or cytokine storm can include a combination of an infectious stimulus, infectious condition, or infectious syndrome and a non-infectious stimulus, non-infectious condition, or non-infectious syndrome.
[0022] In some embodiments, the cause of cytokine release, cytokine release syndrome, or cytokine storm can include at least one of a viral agent, a bacterial agent, a fungal agent, a parasitic agent, a protozoan agent, or an infectious agent.
[0023] In some embodiments, at least one of IL-1β, IL-1RA, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IP-10, IFN-α, IFN-γ, G-CSF, and TNF-α is reduced in the subject.
[0024] Other features and characteristics of the subject matter of the present disclosure, as well as the method of operation, function of the associated elements and combination of members of the structure, and economy of manufacture, will become more apparent from a consideration of the following description and the appended claims, taken in conjunction with the accompanying drawings, which form a part hereof and in which like reference characters indicate corresponding parts in the various views.
[0025] The accompanying drawings, which are incorporated in and form a part of this specification, illustrate various illustrative and non-limiting aspects of the subject matter of the present disclosure. [Brief description of the drawings]
[0026] [Figure 1A] FIG. 1 shows IL-1β in LPS-stimulated human PBMC at 48 hours. [Figure 1B] FIG. 1 shows IL-6 in LPS stimulated human PBMC at 48 hours. [Figure 1C] FIG. 1 shows TNF-α in LPS stimulated human PBMC at 48 hours. [Figure 2A] FIG. 1 shows the results of a CD19 CAR-T co-culture assay with CD19 tumor cells (Raji) at 6 hours, showing CAR-T-mediated tumor targeting in the presence of increasing concentrations of C-2250 (E:T ratio of 5:1). [Figure 2B] FIG. 1 shows the results of a CD19 CAR-T co-culture assay with CD19 tumor cells (Raji) at 6 hours, showing CAR-T-mediated tumor targeting in the presence of increasing concentrations of C-2250 (E:T ratio of 10:1). [Figure 2C] FIG. 1 shows the results of a CD19 CAR-T co-culture assay with CD19 tumor cells (Raji) at 6 hours, showing CAR-T-mediated tumor targeting in the presence of increasing concentrations of C-2250 (E:T ratio of 20:1). [Figure 3A] FIG. 1 shows the results of a CD19 CAR-T co-culture assay with CD19 tumor cells (Raji) at 24 hours, showing CAR-T-mediated tumor targeting in the presence of increasing concentrations of C-2250 (E:T ratio of 5:1). [Figure 3B] FIG. 1 shows the results of a CD19 CAR-T co-culture assay with CD19 tumor cells (Raji) at 24 hours, showing CAR-T-mediated tumor targeting in the presence of increasing concentrations of C-2250 (E:T ratio of 10:1). [Figure 3C]FIG. 1 shows the results of a CD19 CAR-T co-culture assay with CD19 tumor cells (Raji) at 24 hours, showing CAR-T-mediated tumor targeting in the presence of increasing concentrations of C-2250 (E:T ratio of 20:1). [Figure 4] FIG. 1 shows the effect of C-2250 on CD19 CAR-T cell-mediated IL-2 cytokine release across different effector to target ratios. [Diagram 5] FIG. 1 shows the effect of C-2250 on CD19 CAR-T cell-mediated TNF-α cytokine release across different effector-to-target ratios. [Figure 6] FIG. 1 shows the effect of C-2250 on CD19 CAR-T cell-mediated IFN-γ cytokine release across different effector-to-target ratios. [Figure 7] FIG. 1 shows target cell cytotoxicity of BLINCYTO™ in Ramos cells of tested donors. [Figure 8] FIG. 1 shows the effect of C-2250 on BLINCYTO™-mediated cytotoxicity towards CD19+ tumor target cells. [Figure 9A] FIG. 1 shows the effect of BLINCYTO™ on IL-1β cytokine release in donors tested. [Figure 9B] FIG. 1 shows the effect of C-2250 on BLINCYTO™ T cell-mediated IL-1β cytokine release in the donors tested. [Figure 10A] FIG. 1 shows the effect of BLINCYTO™ on IL-2 cytokine release in donors tested. [Figure 10B] FIG. 1 shows the effect of C-2250 on BLINCYTO™ T cell-mediated IL-2 cytokine release in the donors tested. [Figure 11A] FIG. 1 shows the effect of BLINCYTO™ on IL-6 cytokine release in donors tested. [Figure 11B]FIG. 1 shows the effect of C-2250 on BLINCYTO™ T cell-mediated IL-6 cytokine release in the donors tested. [Figure 12A] FIG. 1 shows the effect of BLINCYTO™ on TNF-α cytokine release in donors tested. [Figure 12B] FIG. 1 shows the effect of C-2250 on BLINCYTO™ T cell-mediated TNF-α cytokine release in the donors tested. [Figure 13A] FIG. 1 shows the effect of BLINCYTO™ on IFN-γ cytokine release in donors tested. [Figure 13B] FIG. 1 shows the effect of C-2250 on BLINCYTO™ T cell-mediated IFN-γ cytokine release in the donors tested. [Figure 14] FIG. 1 shows the effect of C-2250 on tumor target cytotoxicity in the absence of BLINCYTO™. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0027] While aspects of the subject matter of the present disclosure may be embodied in a variety of forms, the following description and the accompanying drawings are intended to disclose merely some of these forms as illustrative examples of the subject matter encompassed by the present disclosure, and therefore, the subject matter of the present disclosure is not intended to be limited to the forms or embodiments so described and illustrated.
[0028] To facilitate understanding of the present invention, a number of terms are defined below. Terms defined herein have meanings as commonly understood by one of ordinary skill in the art relevant to the present invention. Terms such as "a", "an" and "the" are not intended to refer to a singular entity only, but include general classifications to which specific examples may be described. While the terminology herein is used to describe specific embodiments of the present invention, their use does not define the present invention, except as outlined in the claims.
[0029] Cytokines are small secreted proteins required for immune cell signaling, activation, and recruitment of other inflammatory cells. Some examples of cytokines include IL-1β, IL-1RA, IL-2Rα, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IL-17, IL-18, IP-10, IFN-α, IFN-γ, MCP-3, MCP-1, M-CSF, G-CSF, MIP-1a, and TNF-α. Some examples of chemokines include CCL5, CXCL8, CXCL1, CXCL2, CXCL10, CCL2, CCL7, CXCL6, CXCL11, CCL2, CCL3, CCL4, CCL7, CCL8, and CCL20. Certain cytokines / chemokines are involved in various diseases, disorders, and pathologies.
[0030] Cytokine release syndrome is a form of systemic inflammatory response syndrome that occurs as a complication of some diseases or infections, and is also an adverse effect of immunotherapy drugs, such as some monoclonal antibody drugs and adoptive T cell therapy drugs. Cytokine release syndrome is a condition that can occur after treatment with some types of immunotherapy drugs, such as monoclonal antibodies and CAR-T cells. Cytokine release syndrome is caused by the rapid release of large amounts of cytokines into the blood from immune cells affected by immunotherapy drugs. Cytokines are immune substances that have many different effects in the body. Signs and symptoms of cytokine release syndrome include fever, nausea, headache, rash, rapid heartbeat, low blood pressure, and difficulty breathing. Most patients have a mild reaction, but sometimes the reaction can be severe or life-threatening.
[0031] The Common Terminology Criteria for Adverse Event Classification for CRS are as follows: Grade 1: mild reaction, interruption of infusion not indicated, no intervention indicated; Grade 2: interruption of therapy or infusion indicated but rapidly responding to symptomatic medication (e.g., antihistamines, NSAIDs, anesthetics, IV fluids), administered prophylactically for ≤24 hours; Grade 3: prolonged (e.g., not rapidly responding to symptomatic medication and / or brief interruption of infusion), recurrence of symptoms after initial improvement, hospitalization indicated for clinical sequelae (e.g., renal dysfunction, pulmonary infiltrates); Grade 4: life-threatening outcome, vasopressors or ventilatory support indicated; Grade 5: death.
[0032] The National Cancer Institute has developed a grading scheme for the severity of CRS: grade 1 includes fever and constitutional symptoms, grade 2 includes hypotension responsive to fluid / low-dose vasopressors and grade 2 organ toxicity, grade 3 includes shock requiring high-dose / multiple vasopressors, hypoxia with a fraction of inspired oxygen (FiO2) of 40% or greater, and grade 3 organ toxicity, and grade 4 includes the need for mechanical ventilation and grade 4 organ toxicity.
[0033] As used herein, the term "cytokine storm" refers to the dysregulation of proinflammatory cytokines that leads to adverse events, toxicity, and disease, and is also referred to as "cytokine storm," "cytokine release syndrome," or "inflammatory cascade." Often, cytokine storm or cytokine cascade is referred to as part of a sequence, since typically one cytokine leads to the production of multiple other cytokines that can enhance and amplify the immune response. In general, these proinflammatory mediators are divided into two subgroups: early mediators and late mediators. For example, early mediators such as tumor necrosis factor, interleukin-1, and interleukin-6 are not sufficient therapeutic targets to re-establish homeostatic balance, since they dissipate within the time frame that patients travel to the clinic and receive medical treatment. In contrast, the so-called "late mediators" have been targeted because patients find themselves ill during this later "inflammatory cascade."
[0034] Infectious diseases commonly associated with a "cytokine storm" include, but are not limited to, malaria, avian influenza, smallpox, pandemic influenza, adult respiratory distress syndrome (ARDS), and severe acute respiratory syndrome (SARS). Certain specific infectious agents include, but are not limited to, the following: the infectious disease is selected from at least one of Ebola virus, Marburg virus, Crimean-Congo hemorrhagic fever (CCHF) virus, South American hemorrhagic fever virus, Dengue virus, Yellow fever virus, Rift Valley fever virus, Omsk hemorrhagic fever virus, Kyasanur Forest virus, Junin virus, Machupo virus, Sabia virus, Gunarito virus, Garissa virus, Ilesha virus, or Lassa fever virus.
[0035] Conditions commonly associated with a "cytokine storm" include, but are not limited to, sepsis, systemic inflammatory response syndrome (SIRS), cachexia, septic shock syndrome, traumatic brain injury (e.g., cerebral cytokine storm), graft-versus-host disease (GVHD), or the result of treatment with immunotherapeutic agents, e.g., activated immune cells, IL-2-activated T cells, anti-CD19 chimeric antigen receptor (CAR) T cells.
[0036] In general, cytokine storm is a healthy systemic expression of an active immune system. The present invention can be used to treat, prevent, inhibit, reduce, or eliminate some or most of the intensified immune response that results in the release of a "cytokine storm" that may include more than 150 inflammatory mediators (cytokines, oxygen free radicals, and coagulation factors), e.g., caused by rapidly proliferating and highly activated T cells or natural killer (NK) cells, among others. Before or during a cytokine storm, both proinflammatory cytokines (such as tumor necrosis factor-α, interleukin-1, and interleukin-6) and anti-inflammatory cytokines (such as interleukin-10 and interleukin-1 receptor antagonist (IL-1RA)) are significantly elevated, e.g., in serum. This excessive release of inflammatory mediators causes a "cytokine storm".
[0037] Without rapid intervention as shown by the present invention, cytokine storm can lead to permanent lung damage and often death. End-stage symptoms of cytokine storm include, but are not limited to, hypotension, tachycardia, respiratory distress, fever, ischemia or insufficient tissue perfusion, uncontrollable bleeding, severe metabolic dysregulation, and multiple organ failure. Death from infectious diseases such as Ebola virus infection is not caused by the virus itself, but rather by cytokine storm, which causes uncontrollable bleeding, severe metabolic dysregulation, hypotension, tachycardia, respiratory distress, fever, ischemia or insufficient tissue perfusion, and multiple organ failure.
[0038] As used herein, the phrase "susceptible to unwanted cytokine release, cytokine release syndrome, or cytokine storm" refers to a subject that has come into contact with, is coming into contact with, or will come into contact with, one or more environmental agents, pollutants, chemicals, drugs, foods, diseases, treatment regimens, disorders, and conditions that induce unwanted cytokine release, cytokine release syndrome, or cytokine storm in the subject.
[0039] As used herein, the terms "substantially" and "substantially" refer to a considerable degree or extent. For example, when used in conjunction with an event, circumstance, characteristic, or property, the terms can refer not only to the exact occurrence of the event, circumstance, characteristic, or property, but also to a close approximation of the event, circumstance, characteristic, or property, such as to illustrate the typical tolerance level or variability of the examples described herein.
[0040] As used herein, the term "about" is used to provide flexibility to the endpoints of a numerical range by specifying that a given value may be "a little above" or "a little below" the endpoint. The flexibility of this term may depend on the particular variable, and is within the knowledge of one of ordinary skill in the art to determine based on experience and the relevant descriptions herein. For example, in one embodiment, the flexibility may be within about ±10% of the numerical value. In another embodiment, the flexibility may be within about ±5% of the numerical value. In further embodiments, the flexibility may be within about ±2%, ±1%, or ±0.05% of the numerical value.
[0041] Generally, in this specification, the term "or" includes "and" and "and / or."
[0042] As used herein, a number of compounds or processes may be presented in a common list for convenience. However, these lists should be construed as though each member of the list is individually identified as a separate and unique member. Thus, unless indicated to the contrary, each member of such a list should not be construed as being de facto equivalent to any other member of the same list solely based on their presentation in a common group.
[0043] In some embodiments, the compounds of the present invention may be available in the form of free acids, free bases, pharma- ceutically acceptable salts, pharma-ceutically acceptable hydrates, pharma-ceutically acceptable esters, pharma-ceutically acceptable solvates, pharma-ceutically acceptable prodrugs, pharma-ceutically acceptable metabolites, and pharma-ceutically acceptable stereoisomers. All of these forms are within the scope of the present invention. In practice, the use of these forms is equivalent to the use of neutral compounds.
[0044] "Pharmaceutically acceptable salt", "hydrate", "ester" or "solvate" refers to a salt, hydrate, ester or solvate of a compound of the present invention that has the desired pharmacological activity and is not biologically or otherwise undesirable. Organic acids can be used to form salts, hydrates, esters or solvates, such as acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, p-toluenesulfonate, bisulfate, sulfamate, sulfate, naphthylate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, tosylate and undecanoate salts. Inorganic acids can be used to form salts, hydrates, esters or solvates, such as hydrochloride, hydrobromide, hydroiodide and thiocyanate salts. Other pharma-ceutically acceptable salts include, but are not limited to, hydrochloride, hydrobromide, sulfate, phosphate, tartrate, fumarate, maleate, oxalate, acetate, propionate, succinate, mandelate, mesylate, besylate and tosylate salts.
[0045] Salts, hydrates, esters or solvates can also be formed with organic bases. Pharmaceutically acceptable base addition salts of acidic compounds can be formed with organic and inorganic bases by conventional methods. Examples include hydroxides, carbonates and bicarbonates of alkali metals and alkaline earth metals such as sodium hydroxide, potassium hydroxide, calcium hydroxide, potassium carbonate, sodium bicarbonate, magnesium carbonate, ammonia, primary, secondary and tertiary amines, etc. Aluminum salts of the present compounds can also be obtained by treating the corresponding sodium salt with a suitable aluminum complex, such as aluminum chloride hexahydrate. Non-toxic organic bases include, but are not limited to, triethylamine, butylamine, piperazine and tri(hydroxymethyl)-methylamine. Examples of suitable base salts, hydrates, esters or solvates include hydroxides, carbonates and bicarbonates of ammonia, alkali metal salts such as sodium salt, lithium salt and potassium salt, alkaline earth metal salts such as calcium salt and magnesium salt, aluminum salt, and zinc salt. Suitable organic bases for forming pharma-ceutically acceptable base addition salts, hydrates, esters or solvates of the compounds of the present invention include organic bases that are non-toxic and strong enough to form such salts, hydrates, esters or solvates.For illustrative purposes, such organic bases can include mono-, di- and trialkylamines such as methylamine, dimethylamine, triethylamine and dicyclohexylamine; mono-, di- or trihydroxyalkylamines such as monoethanolamine, diethanolamine and triethanolamine; amino acids such as arginine and lysine; guanidine; N-methyl-glucosamine; N-methyl-glucamine; L-glutamine; N-methyl-piperazine; morpholine; ethylenediamine; N-benzyl-phenethylamine; (trihydroxy-methyl)aminoethane and the like.See, for example, "Pharmaceutical Salts," J. Pharm. Sci., 66:1, 1-19 (1977).Thus, basic nitrogen-containing groups can be quaternized with agents including lower alkyl halides, such as methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides; dialkyl sulfates, such as dimethyl sulfate, diethyl sulfate, dibutyl sulfate, and diamyl sulfate; long chain halides, such as decyl, lauryl, myristyl, and stearyl chlorides, bromides, and iodides; and aralkyl halides, such as benzyl and phenylethyl bromides.
[0046] Salts, hydrates, esters or solvates of basic compounds can be prepared by dissolving the free base of the oxathiazine-like compound in an aqueous or aqueous alcoholic solution or other suitable solvent containing the appropriate acid or base and isolating the salt by evaporating the solution. Alternatively, the free base of the oxathiazine-like compound can be reacted with an acid and the oxathiazine-like compound bearing an acidic group can be reacted with a base, the reaction being carried out in an organic solvent, in which case the salt can be isolated directly or obtained by concentrating the solution.
[0047] A "pharmaceutical acceptable prodrug" refers to a derivative of a compound of the present invention that exhibits its pharmacological effect(s) after undergoing biotransformation. Prodrugs are formulated to improve chemical stability, improve patient acceptance and compliance, improve bioavailability, extend duration of action, improve organ selectivity, improve formulation (e.g., increase hydrosolubility), and / or reduce side effects (e.g., toxicity). Prodrugs can be readily prepared from the compounds of the present invention using methods known in the art, such as those described in Burger's Medicinal Chemistry and Drug Chemistry, Fifth Ed., Vol. 1, pp. 172-178, 949-982 (1995). For example, the compounds of the present invention can be modified into prodrugs by converting one or more of the hydroxy or carboxy groups into esters. Additionally, N-protected versions of the compounds of the present invention are also included as non-limiting examples of pharmaceutical acceptable prodrugs of the compounds of the present invention.
[0048] "Pharmaceutically acceptable metabolite" refers to a drug that has undergone metabolic transformation. Most drugs become substrates for chemical reactions that can change their physical properties and biological effects after entering the body. These metabolic transformations usually affect the polarity of the compound, changing the way the drug is distributed in and excreted from the body. Also, in some cases, drug metabolism is required for therapeutic effect. For example, anticancer drugs from the antimetabolite group need to be converted to their active form after being transported to cancer cells. Since most drugs undergo some metabolic transformation, the biochemical reactions involved in drug metabolism can be diverse. The main site of drug metabolism is the liver, but other tissues may also be involved.
[0049] Furthermore, certain compositions, concentrations, administration regimens, dosage amounts, syndromes or conditions, steps, etc. may be discussed in the context of a particular embodiment, with the understanding that this is merely for convenience and that such disclosure applies equally to other embodiments found herein. For example, the recitation of the method steps, active agents, kits, or compositions described with respect to a method of treating CRS or cytokine storm should find direct support for aspects related to the following method steps, active agents, kits, or compositions, e.g., inhibiting or reducing neurotoxicity, decreasing or inhibiting cytokine production, treating one or more symptoms or adverse reactions caused by an infectious disease or a condition causing widespread release of cytokines, inhibiting, preventing, or treating vascular leakage, activation of the complement and coagulation cascades inducing disseminated intravascular coagulation (DIC), cardiomyopathy, and / or myocardial dysfunction in a subject at risk for such leakage, activation of the complement and coagulation cascades inducing disseminated intravascular coagulation (DIC), cardiomyopathy, and / or myocardial dysfunction, and / or increasing the maximum tolerated dose of a T cell directed immunotherapeutic, even if those method steps, active agents, kits, or compositions are not re-enumerated in the context of that aspect herein.
[0050] The term "treat" or "treatment" as used herein and well understood in the art, refers to an approach to obtain beneficial or desired results, including clinical results. Beneficial or desired clinical results may include, but are not limited to, alleviation or amelioration of one or more symptoms or pathology, whether detectable or undetectable, reduction in the extent of disease, stabilization (i.e., not worsening) of the disease state, delay or slowing of disease progression, improvement or mitigation of the disease state, reduction in recurrence of disease, and remission (whether partial or complete). "Treat" and "treatment" may also mean prolonging survival compared to expected survival in the absence of treatment. In addition to being useful as a method of treatment, the methods described herein may be useful for prevention or prophylaxis of disease. As used herein, the term "treating" refers to any administration of a compound of the invention and includes (i) preventing or inhibiting the disease (i.e., halting further progression of the disease symptoms and / or symptomology) in a mammal, e.g., a human, experiencing or manifesting the pathology or symptomology of the disease, or (ii) ameliorating the disease (i.e., reversing the disease symptoms and / or symptomology) in a mammal, e.g., a human, experiencing or manifesting the pathology or symptomology of the disease. The term "controlling" includes preventing, treating, eradicating, ameliorating, or otherwise reducing the severity of the condition being controlled.
[0051] Concentrations, amounts, and other numerical data may be expressed or presented in a range format herein. It should be understood that such range formats are used merely for convenience and brevity, and should be interpreted flexibly to include not only the numerical values explicitly recited as the limits of the range, but also all individual numerical values or subranges subsumed within the range, as if each numerical value and subrange were explicitly recited. For example, a numerical range of "about 0.01 to 2.0" should be interpreted to include not only the explicitly recited values of about 0.01 to about 2.0, but also the individual values and subranges within the specified range. Thus, individual values such as 0.5, 0.7, and 1.5, as well as subranges such as 0.5 to 1.7, 0.7 to 1.5, and 1.0 to 1.5, are included in this numerical range. Moreover, such interpretation should be applied regardless of the breadth of the range or the properties described. In addition, it should be noted that all percentages are weight percentages unless otherwise specified.
[0052] In understanding the scope of the present disclosure, the terms "including" or "comprising" and its derivatives, as used herein, are intended to be open-ended terms specifying the presence of the stated features, elements, components, groups, integers, and / or steps, but not excluding the presence of other unstated features, elements, components, groups, integers, and / or steps. The above also applies to words of similar meaning, such as the terms "including" and "having" and their derivatives. The term "consisting" and its derivatives, as used herein, are intended to be closed terms specifying the presence of the stated features, elements, components, groups, integers, and / or steps, but excluding the presence of other unstated features, elements, components, groups, integers, and / or steps. The term "consisting essentially of," as used herein, is intended to specify the presence of the stated features, elements, components, groups, integers, and / or steps, as well as those that do not substantially affect the basic novel property(s) of the features, elements, components, groups, integers, and / or steps. It is understood that reference to any one of these transitional terms (i.e., "comprising," "consisting," or "consisting essentially of") directly supports the substitution of any other transitional term not specifically used. For example, modifying the term "comprising" to "consisting essentially of" is directly supported by this definition.
[0053] Some oxathiazine-like compounds are described in International Application PCT / IB2015 / 059741, filed December 17, 2015, which is incorporated herein by reference in its entirety. In certain embodiments, oxathiazine-like compounds according to formula I are used in accordance with the present invention, where R is H, an in vivo cleavable linker or group, or a group that leaves in aqueous solution, and R1 and R2 are independently H, alkyl, aryl, substituted alkyl, substituted phenyl, substituted aryl, or combinations thereof. In some embodiments, R is an in vivo cleavable linker or group. In some embodiments, the substituted alkyl, substituted phenyl, or substituted aryl may be substituted with any suitable molecule, including, for example, one or more halogens or halogen-containing molecules, one or more hydroxyl groups, one or more acyl groups, one or more acyloxy groups, one or more alkoxy groups, one or more aryl groups, one or more carboxy groups, one or more carbonyl groups, one or more alkylcarboxy groups, one or more alkylsulfonoxy groups, one or more alkylcarbonyl groups, one or more nitro groups, one or more cyano groups, one or more acylamido groups, one or more phenyl groups, one or more tolyl groups, one or more chlorophenyl groups, one or more alkoxyphenyl groups, one or more halophenyl groups, one or more benzoxazole groups, one or more thiazoline groups, one or more benzimidazole groups, one or more oxazole groups, one or more thiazole groups, one or more indole groups, and the like, or combinations thereof. In some embodiments, the alkyl or substituted alkyl may be a C1-C30 alkyl. In some embodiments, the alkyl may be branched or unbranched. In some embodiments, the aryl may be heterocyclic, polycyclic, or monocyclic.
[0054] [ka]
[0055] Exemplary oxathiazine-like compounds include the following: [ka] and isethionic acid hydroxymethylamide.
[0056] In certain preferred embodiments, 2250 (tetrahydro 1,4,5-oxathiazine-4-dioxide, or 1,4,5-oxathiazane-4-dioxide) is used to treat, prevent, inhibit, or reduce cytokine release, CRS, or cytokine storm in accordance with the disclosures herein.
[0057] In certain aspects, the present invention also relates to compositions comprising the compounds described herein, including pharma- ceutically acceptable solutions of the compounds, e.g., pharmaceutical compositions, and orally administrable compositions, such as capsules and tablets, comprising the compositions.
[0058] As used herein, the term "effective amount" or "therapeutically effective amount" refers to that amount of the subject compound that elicits the biological or medical response in a tissue, system, animal or human that is desired by a researcher, veterinarian, physician or other clinician. In one example, a therapeutically effective amount includes about 0.0001 mg / kg to about 10000 mg / kg, about 0.001 mg / kg to about 5000 mg / kg, about 0.01 mg / kg to about 1000 mg / kg, about 0.05 mg / kg to about 750 mg / kg, about 0.1 mg / kg to about 600 mg / kg, about 1 mg / kg to about 500 mg / kg, about 10 mg / kg to about 400 mg / kg, about 20 mg / kg to about 300 mg / kg, about 200 mg / kg to about 500 mg / kg, about 300 mg / kg to about 400 mg / kg, about 250 mg / kg, 300 mg / kg, 400 mg / kg, 420 mg / kg, 450 mg / kg, about 500 mg / kg, or a dosage or range within any of the disclosed ranges of the body weight of the subject.
[0059] The term "administration of" or "administering" a compound, as used herein, should be understood to mean providing to an individual in need of treatment a compound of the present invention in a form that can be introduced into the individual's body, for example, intravenously, subcutaneously, intramuscularly, topically, orally, intraperitoneally, intrathecally, intranasally, intrapulmonary, transdermally, intraocularly, by inhalation, transtracheally, intravitreally, or combinations thereof. In some embodiments, the compounds of the present invention can be administered in any therapeutically useful form and in any therapeutically useful amount, including, but not limited to, oral dosage forms such as tablets, capsules, syrups, suspensions, and the like; injectable dosage forms such as intravenous (IV), intramuscular (IM) or intraperitoneal (IP), intranasal, and the like; enteral or parenteral, transdermal dosage forms including creams, jellies, powders, or patches; buccal dosage forms; inhalation powders, sprays, suspensions, and the like; and rectal suppositories.
[0060] Depending on the particular route of administration desired, a variety of pharma- ceutically acceptable carriers known in the art can be used. These include solid or liquid fillers, diluents, hydrotropes, surfactants, and encapsulating materials. Any pharma- ceutically active material that does not substantially interfere with the activity of one or more oxathiazine-like compounds may be included.
[0061] As used herein, the term "intravenous administration" includes injections, infusions and other methods of intravenous administration.
[0062] The term "pharmaceutically acceptable" as used herein means that the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
[0063] In one aspect, the disclosure includes preventing, inhibiting, or reducing the occurrence of cytokine release, cytokine release syndrome (CRS), or cytokine storm in a subject by administering one or more oxathiazine-like compounds or combinations thereof. In some aspects, the subject is at risk for unwanted cytokine release. In some aspects, the subject is in need of suppressing or downregulating cytokine release. In some aspects, the subject has undergone, may undergo, or will undergo therapy with an agent or regimen expected to result in cytokine release that requires suppression. In some aspects, the subject has undergone, may undergo, or will undergo immunotherapy, T cell guided therapy, chimeric antigen receptor expressing T cell (CAR T cell) therapy, and / or bispecific antibody therapy. In some aspects, the disclosure provides methods and compositions for treating conditions mediated by inflammatory cytokine cascades as disclosed in U.S. Pat. No. 8,715,658 (Tracey), which is incorporated herein by reference in its entirety.
[0064] In some embodiments, conditions mediated by cytokine release include, but are not limited to, appendicitis, peptic, gastric and duodenal ulcers, peritonitis, pancreatitis, ulcerative colitis, pseudomembranous colitis, acute and ischemic colitis, diverticulitis, epiglottitis, achalasia, cholangitis, cholecystitis, hepatitis, Crohn's disease, enteritis, Whipple's disease, asthma, allergies, anaphylactic shock, immune complex disease, organ ischemia, reperfusion injury, organ necrosis, hay fever, sepsis, toxemia, endotoxemia, and the like. Toxic shock, cachexia, hyperpyrexia, eosinophilic granuloma, granulomatosis, sarcoidosis, septic abortion, epididymitis, vaginitis, prostatitis, urethritis, bronchitis, emphysema, rhinitis, cystic fibrosis, interstitial pneumonia, alveolitis, bronchiolitis, pharyngitis, pleuritis, sinusitis, parasitic infection, bacterial infection, viral infection, autoimmune disease, influenza, respiratory syncytial virus infection, herpes infection, HIV infection, hepatitis B virus infection, hepatitis C virus infection, disseminated bacteremia, dengue fever , candidiasis, malaria, filariasis, amebiasis, hydatid cyst, burn, dermatitis, dermatomyositis, sunburn, urticaria, warts, wheals, vasculitis, vasculitis, endocarditis, arteritis, atherosclerosis, thrombophlebitis, pericarditis, myocarditis, myocardial ischemia, periarteritis nodosa, rheumatic fever, celiac disease, congestive heart failure, adult respiratory distress syndrome, coronaviruses, SARS-CoV-2, Middle East Respiratory Syndrome (MERS), multisystem inflammatory syndrome, coronavirus-induced inflammatory syndrome, Kawasaki disease , meningitis, encephalitis, cerebral infarction, cerebral embolism, Guillain-Barré syndrome, neuritis, neuralgia, spinal cord injury, paralysis, uveitis, arthritis, arthralgia, osteomyelitis, fasciitis, Paget's disease, gout, periodontal disease, rheumatoid arthritis, synovitis, myasthenia gravis, thyroiditis, systemic lupus erythematosus, Goodpasture's syndrome, Behcet's syndrome, allograft rejection, graft versus host disease, ankylosing spondylitis, Berger's disease, Reiter's syndrome, and Hodgkin's disease.
[0065] In one aspect, the present disclosure provides a method for treating neuromyelitis optica spectrum disorder (NMSOD), a rare, relapsing autoimmune disease of the central nervous system. IL-6 signaling has been implicated as playing a key role in the inflammation that occurs in NMSOD, particularly in the initiation of flare-ups. Compounds of the present disclosure inhibit the production of inflammatory cytokines, including IL-6, to treat patients suffering from or at risk of developing NMSOD.
[0066] In some aspects, the disclosure includes monitoring a subject for fever as a clinical sign of impending cytokine release, CRS, or cytokine storm in a patient at risk for unwanted cytokine release or in need of suppressing or downregulating cytokine release, and administering one or more oxathiazine-like compounds of the disclosure within about 24 hours, e.g., within about 1 hour, within 2 hours, within 3 hours, within 4 hours, within 5 hours, within 6 hours, within 8 hours, within 10 hours, or within 12 hours, of the onset of fever. For example, the patient may be undergoing immunotherapy or one or more T cell induction therapies.
[0067] In some aspects, the disclosure includes monitoring a subject for one or more biomarkers indicative of impending cytokine release, CRS, or cytokine storm in a patient undergoing T cell induction therapy, and administering one or more oxathiazine-like compounds of the disclosure within about 24 hours, e.g., within about 1 hour, within 2 hours, within 3 hours, within 4 hours, within 5 hours, within 6 hours, within 8 hours, within 10 hours, or within 12 hours, of detection of the one or more biomarkers. In some embodiments, a subject undergoing T cell induction therapy is monitored for serum, blood, or tissue levels of one or more of IL-1β, IL-1RA, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IP-10, IFN-α, IFN-γ, G-CSF, and TNF-α, and one or more oxathiazine-like compounds of the present disclosure are administered within about 6 hours, e.g., within about 0.5 hours, within 1 hour, within 2 hours, within 3 hours, within 4 hours, within 5 hours, within 6 hours, of detecting an increase in serum, blood, or tissue levels of one or more of IL-1β, IL-1RA, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IP-10, IFN-α, IFN-γ, G-CSF, and TNF-α above a threshold level, or a percentage above baseline. + T cells and CD8 + Monitor the levels and ratios of T cells and CD4 + Or, within about 6 hours, e.g., within about 0.5 hours, within 1 hour, within 2 hours, within 3 hours, within 4 hours, within 5 hours, within 6 hours, of detecting an increase in serum, blood, or tissue levels of one or more of the CD4 / CD8 ratios, or a percentage above baseline, one or more oxathiazine-like compounds of the disclosure are administered.
[0068] In some embodiments, the disclosure includes monitoring a subject using a PBMC assay. In some embodiments, the disclosure includes monitoring a subject using a whole blood (WB) assay.
[0069] In one aspect, the disclosure includes preventing, inhibiting, or reducing cytokine release, including but not limited to, release of IL-1β, IL-1RA, IL-2Rα, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IL-17, IL-18, IP-10, IFN-α, IFN-γ, MCP-3, MCP-1, M-CSF, G-CSF, MIP-1a, TNF-α, CCL5, CXCL8, CXCL1, CXCL2, CXCL10, CCL2, CCL7, CXCL6, CXCL11, CCL2, CCL3, CCL4, CCL7, CCL8, and CCL20, in a subject prior to, during, or after the onset of cytokine release, e.g., prior to, during, or after a therapy, e.g., treatment with an immunotherapeutic, e.g., a T cell directing therapy.
[0070] In another aspect, the method and composition of the present disclosure surprisingly does not reduce the killing of targeted cancer cells by such immunotherapeutic agents.Before the present disclosure, known agents used to shut down cytokines shut down cytokines at the expense of reducing cytotoxicity to targeted cancer cells.In contrast, as illustrated in Example 3, it has been found that the composition and method of the present disclosure surprisingly does not reduce the killing of targeted cancer cells by such immunotherapeutic agents.
[0071] In one aspect, the disclosure includes inhibiting, reducing, or preventing the release of IFN-γ. Secreted IFN-γ induces activation of other immune cells, most importantly macrophages. Activated macrophages produce excess amounts of additional cytokines such as IL-6, TNF-α, and IL-10. TNF-α induces flu-like symptoms similar to IFN-γ with fever, general malaise, and fatigue, but also causes watery diarrhea, vascular leakage, cardiomyopathy, lung damage, and synthesis of acute phase proteins. It is known in the art that various therapeutic agents, including anti-cancer therapeutic agents and interferon agents, induce flu-like symptoms in patients. The disclosure includes treating, inhibiting, reducing, or preventing drug-induced flu-like symptoms in a subject at risk for drug-induced flu-like symptoms by administering one or more oxathiazine-like compounds to the subject.
[0072] IL-6 is responsible for many of the cardinal symptoms of CRS and cytokine storm. Through trans-signaling, IL-6 causes the hallmark symptoms of severe CRS and cytokine storm, namely vascular leakage and activation of the complement and coagulation cascades inducing disseminated intravascular coagulation (DIC). In addition, IL-6 may contribute to the cardiomyopathy often seen in patients with CRS and cytokine storm by promoting myocardial dysfunction. The present disclosure includes inhibiting, preventing, reducing, or treating vascular leakage, activation of the complement and coagulation cascades inducing disseminated intravascular coagulation (DIC), cardiomyopathy, and / or myocardial dysfunction in a subject at risk for vascular leakage, activation of the complement and coagulation cascades inducing disseminated intravascular coagulation (DIC), cardiomyopathy, and / or myocardial dysfunction by administering one or more oxathiazine-like compounds to a subject in need thereof. Inflammatory signals such as LPS induce the release of inflammatory cytokines by activating the transcription factor NFkB (NFκB). Upon activation, NFkB translocates from the cytoplasm to the nucleus and activates the expression of a broad set of genes, including genes that produce chemokines and inflammatory cytokines such as IL-1, IL-6, TNFα, and INFγ. Inhibition of the production and release of chemokines and inflammatory cytokines by the oxathiazine-like compounds of the present disclosure indicates that the oxathiazine-like compounds of the present disclosure are inhibitors of the NFkB pathway. In some embodiments, the oxathiazine-like compounds of the present disclosure may directly or indirectly inhibit NFkB.
[0073] In one embodiment, the patient is treated with one or more oxathiazine-like compounds or combinations thereof administered intravenously, orally, or a combination thereof. In one embodiment, the patient is treated with 2250 (also referred to as "compound 2250" or "C-2250") administered intravenously, orally, or a combination thereof. In one embodiment, the composition is administered prior to, concurrently with, or following a therapy, such as immunotherapy, T cell induction therapy, CAR T cell therapy, and antibody therapy, such as monoclonal antibody therapy and / or bispecific antibody therapy.
[0074] In one aspect, the patient is administered one or more oxathiazine-like compounds or combinations thereof in combination therapy with one or more antitumor drugs, such as nucleoside analogs, antifolates, antimetabolites, topoisomerase I inhibitors, anthracyclines, podophyllotoxins, taxanes, vinca alkaloids, alkylating agents, platinum compounds, antibodies, tyrosine kinase inhibitors, mTOR inhibitors, retinoids, immunomodulators, histone deacetylase inhibitors, plant alkaloids, and antitumor antibiotics. For example, the patient may be administered one or more oxathiazine-like compounds or combinations thereof in combination with non-protein-based anticancer drugs, such as oxaliplatin and lenalidomide. In one aspect, a patient is administered one or more oxathiazine-like compounds or combinations thereof in combination with an antibody-based therapy such as antithymocyte globulin (ATG), CD28 superagonist TGN1412, rituximab, obinutuzumab, alemtuzumab, brentuximab, dacetuzumab, and nivolumab. In one aspect, a patient is administered one or more oxathiazine-like compounds or combinations thereof in combination with an immunotherapy such as a T cell guided therapy and an antibody.
[0075] In one embodiment, a patient is administered one or more oxathiazine-like compounds or a combination thereof in combination with a donor stem cell transplant.
[0076] In one embodiment, a patient is administered one or more oxathiazine-like compounds or combinations thereof in combination with an interferon-containing medication, such as interferon alpha, interferon beta, or interferon gamma, or an interleukin-containing medication.
[0077] In one embodiment, the patient is administered one or more oxathiazine-like compounds or combinations thereof in combination with erythropoietin, granulocyte colony stimulating factor, or bone morphogenetic protein.
[0078] In some aspects, the disclosure includes administering one or more oxathiazine-like compounds in combination with one or more of tocilizumab, antihistamines, antipyretics, anti-inflammatory compounds, corticosteroids, glucocorticoids, TNF inhibitors (e.g., etanercept), siltuximab, T cell depleting antibody therapies such as alemtuzumab and antithymocyte globulin (ATG), IL-1R system inhibitors (anakinra), ibrutinib, and cyclophosphamide.
[0079] The compounds of the present disclosure, particularly compound 2250, have been found to be highly soluble in water. In certain embodiments, polyvinylpyrrolidone (PVP) is not required to enhance solubility. For example, a 3.2% solution of 2250 is isotonic.
[0080] The compounds according to the invention can be administered by any suitable method.Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the composition to be provided is mixed with at least one inert pharma- ceutically acceptable excipient and / or filler or extender (e.g., starch, lactose, sucrose, glucose, mannitol, and silicic acid), binder (e.g., carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and gum arabic), humectant (e.g., glycerol), disintegrating agent (e.g., agar-agar, calcium carbonate, potato starch, tapioca starch, alginic acid, certain silicates, and sodium carbonate), solution retarder (e.g., paraffin), absorption accelerator (e.g., quaternary ammonium compounds), wetting agent (e.g., cetyl alcohol and glycerol monostearate), absorbent (e.g., kaolin and bentonite clay), and lubricant (e.g., talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate), and mixtures thereof. In the case of capsules, tablets, and pills, the dosage forms may contain buffering agents.
[0081] Solid compositions of a similar type can be employed as fillers in soft and / or hard gelatin capsules using excipients such as lactose or milk sugar, and high molecular weight polyethylene glycols, and the like. Solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells, such as enteric coatings and other coatings known in the pharmaceutical formulating art. These may optionally contain opacifying agents and may be composed so as to release a given composition(s) only in, or targeted to, a certain part of the intestinal tract, optionally in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. Solid compositions of a similar type can be employed as fillers in soft and hard gelatin capsules using excipients such as lactose or milk sugar, and high molecular weight polyethylene glycols, and the like.
[0082] In certain embodiments, the capsule may contain an excipient blend containing one or more of hydroxypropylmethylcellulose (HPMC), gelatin, and fish gelatin. In certain embodiments, the capsule may contain Compound 2250 in combination with taurolidine and / or taurultam. The capsule may optionally further contain one or more of lycopene, ellagic acid (a polyphenol), curcumin, piperine, delphinidin, resveratrol, isothiocyanates such as sulforaphane, capsaicin, and piperlongumine.
[0083] The compounds of the claimed invention can achieve higher blood levels when used in microparticle or nanoparticle form. The present invention includes microparticles and / or nanoparticles of the compounds of the present disclosure in tablet form or encapsulated.
[0084] In certain embodiments, the disclosure relates to orally administering an oxathiazine-like compound to a patient. In some embodiments, the oxathiazine-like compound is formulated into a capsule or tablet. In certain embodiments, the oral dosage form contains about 50 mg to 1000 mg of the oxathiazine-like compound. In certain embodiments, the oral dosage form contains about 100 mg to 500 mg of the oxathiazine-like compound. In certain embodiments, the oral dosage form contains about 200 mg to 400 mg of the oxathiazine-like compound. In certain embodiments, the oral dosage form contains about 250 mg to 350 mg of the oxathiazine-like compound. In certain embodiments, the oxathiazine-like compound is C-2250.
[0085] In some embodiments, the oxathiazine-like compound is provided in the composition at a concentration of about 0.01 μg / ml to about 500 μg / ml. In some embodiments, the oxathiazine-like compound is provided in the composition at a concentration of about 0.1 μg / ml to about 100 μg / ml. In some embodiments, the oxathiazine-like compound is provided in the composition at a concentration of about 10 μg / ml to about 50 μg / ml.
[0086] In some embodiments, the oxathiazine-like compound is provided in the composition at a concentration of about 0.001 wt% to about 5 wt%, about 0.01 wt% to about 3.5 wt%, about 0.1 wt% to about 3 wt%, about 0.5 wt% to about 2.5 wt%, or about 1 wt% to about 2 wt%. In some embodiments, the oxathiazine-like compound is provided in the composition at a concentration of about 0.01% to about 1.5%. In some embodiments, the oxathiazine-like compound is provided in the composition at a concentration of about 0.1% to about 1%. In some embodiments, the oxathiazine-like compound is provided in the composition at a concentration of about 100 μM to about 5000 μM, about 250 μM to about 2500 μM, about 500 μM to about 2000 μM, about 750 μM to about 1500 μM, about 1000 μM to about 1250 μM, or any other concentration within the recited range.
[0087] In some embodiments, the oxathiazine-like compound is provided in a composition in unit dosage form. As used herein, a "unit dosage form" is a composition containing an amount of the oxathiazine-like compound suitable for administration to an animal, such as a mammal, e.g., a human subject, in a single dose in accordance with good medical practice. These compositions may contain from about 0.1 mg (milligram) to about 500 mg, e.g., from about 5 mg to about 350 mg, of the oxathiazine-like compound. The frequency of treatment with the compositions of the invention can be varied to achieve and maintain the desired target plasma levels. Thus, non-limiting examples of treatment schedules include daily, twice daily, three times daily, weekly, biweekly, monthly, and combinations thereof. Alternatively, the compositions of the invention can be administered as a continuous infusion.
[0088] In certain embodiments, one or more oxathiazine-like compounds of the present disclosure are administered to a subject prior to administration of a therapeutic agent expected to cause cytokine release in the subject. For example, in one embodiment, one or more oxathiazine-like compounds of the present disclosure are administered about 12 hours to 96 hours, such as 24 hours, 48 hours, or 72 hours, prior to administration of a therapeutic agent expected to cause cytokine release in the subject. In one embodiment, one or more oxathiazine-like compounds of the present disclosure are administered in a single dose or multiple doses prior to administration of a therapeutic agent expected to cause cytokine release in the subject. In certain embodiments, one or more oxathiazine-like compounds of the present disclosure are administered to a subject simultaneously with a therapeutic agent expected to cause cytokine release in the subject. In certain embodiments, the oxathiazine-like compound is administered to a subject within about 1 hour to about 24 hours, about 2 hours to about 18 hours, about 6 hours to about 15 hours, about 4 hours to about 12 hours, or any time range within the disclosed ranges, after administration to the subject of a therapeutic agent expected to result in cytokine release in the subject.
[0089] In certain embodiments, one or more oxathiazine-like compounds of the present disclosure are administered according to a regimen during a period during which CRS or a cytokine storm is anticipated to occur. For example, in one embodiment, one or more oxathiazine-like compounds of the present disclosure are administered daily, every other day, every other week, or weekly for a period of 3 to 10 weeks, 4 to 8 weeks, or 4 to 6 weeks prior to, during, and / or after administration of a therapeutic agent, e.g., a T cell inducing therapeutic agent, anticipated to result in cytokine release in the subject.
[0090] In certain embodiments, it is advantageous to administer one or more oxathiazine-like compounds of the present disclosure prophylactically prior to the initiation of treatment. For example, because CRS or cytokine storm resulting from bispecific antibody therapy is often observed within minutes to hours of administration of the bispecific antibody, it is particularly advantageous to administer a cytokine release inhibitor compound of the present disclosure prior to administration of the bispecific antibody therapy.
[0091] In one aspect, the oxathiazine-like compound is provided in a composition and administered to a subject in need thereof in a total daily dosage that may be from about 0.001 g to about 1000 g, e.g., from about 0.01 g to about 500 g, 0.1 g to 300 g, 0.5 g to 200 g, 1 g to 100 g, or any amount within the ranges recited. The daily dosage may be administered in the form of an orally administrable composition. The daily dosage may be administered in the form of a capsule, tablet, or pharma- ceutically acceptable solution. The daily dosage may be administered in a form that contains a compound of the present disclosure, e.g., 2250, in a concentration of from about 0.01% to about 3% (w / v).
[0092] The daily dosage may be administered in a form containing compound 2250 at a concentration of about 0.01 μg / ml to about 1000 μg / ml. The daily dosage may be administered in a form containing one or more solubilizing agents, such as polyols.
[0093] An effective dosage of the oxathiazine-like compound is provided in the composition and may include a dosage unit containing about 0.01 mg / kg to 500 mg / kg, about 1 mg / kg to 100 mg / kg, or about 5 mg / kg to 50 mg / kg of the oxathiazine-like compound per day, hi some embodiments, the dosage unit is administered every other day, every other week, or every week.
[0094] The specific effective dose for any particular patient will depend on a variety of factors, including the severity or likelihood of cytokine release, cytokine release syndrome (CRS), or cytokine storm, the activity of the particular compound used, the age, weight, general health, sex, and diet of the patient, the preparation of the particular compound, the time and route of administration, the duration of administration, the therapeutic agents used in combination with or simultaneously with the particular compound used, and similar factors known in the medical arts. The effective dose can also be changed over time as the cytokine release syndrome or cytokine storm worsens or improves. In the case of chronic conditions, an effective dose can be administered to the subject for days, weeks, or months. The number and frequency of administration or co-administration can vary depending on the likelihood or severity of cytokine release, CRS, and cytokine storm, and the patient-specific response to the particular compound administered and / or the second therapeutic active agent administered. EXAMPLES
[0095] Aspects of the present disclosure will be further described with reference to the following examples, which are provided for illustrative purposes only and should not be used to limit the scope or interpret the present invention.
[0096] Example 1 The ability of C-2250 to suppress cytokine release from primary human peripheral blood mononuclear cells (PBMCs) in vitro was assessed. Lipopolysaccharide (LPS) inhibition by C-2250 was measured. PBMCs from five individual normal healthy human volunteers were incubated with C-2250 followed by stimulation with LPS for 48 hours. Detection of three different cytokines was performed using an antibody capture bead-based kit and flow cytometry analysis.
[0097] Cryopreserved PBMCs (IQ Biosciences, Cat. No. IQB-PBMC103) from five healthy human donors were thawed and cultured in RPMI 1640 medium (Gibco RPMI-1640 medium (ATCC, Cat. No. 30-2001) supplemented with 10% FCS, 2 mM L-glutamine, 100 IU / mL penicillin, 100 μg / mL streptomycin, and 1 mM sodium pyruvate (all from ThermoFisher) and counted using an automated cell counter (Countess II) prior to the experiment. The cells had a viability of over 85% as measured by a FL automated cell counter (ThermoFisher, Cat. No. AMQAF1000). For C-2250, a 73 mM stock was prepared in sterile lactated Ringer's solution by adding 100 mg of C-2250 to 10 mL of lactated Ringer's solution within 2 hours prior to the start of the assay. The pH of the solution was adjusted to 7.3 prior to use in the assay. 1.0 × 10 7 100 μl of PBMCs at 10 cells / mL were washed and resuspended in tissue culture medium containing a fixed concentration (1 ng / ml) of LPS from E. coli serotype O111:B4. After 48 hours of LPS stimulation at 37°C and 5% CO2, tissue culture supernatants were harvested for cytokine analysis. C-2250 was used at concentrations of 500 μM, 1000 μM, and 1500 μM.
[0098] Donor demographics were as follows:
[0099] [Table 1]
[0100] The results for IL-1β, IL-6, and TNF-α are summarized in Figure 1A, Figure 1B, and Figure 1C. Figure 1A shows IL-1β in LPS-stimulated human PBMC at 48 hours (lower limit of detection 0.62 pg / ml; upper limit of detection 15228 pg / ml). Figure 1B shows IL-6 in LPS-stimulated human PBMC at 48 hours (lower limit of detection 1.0 pg / ml; upper limit of detection 19360 pg / ml). Figure 1C shows TNF-α in LPS-stimulated human PBMC at 48 hours (lower limit of detection 0.39 pg / ml; upper limit of detection 10000 pg / ml). Each symbol represents the mean value of triplicate analyses of a single donor. Each bar per treatment group represents the mean value across all donors, averaging the triplicate values for each donor.
[0101] All individual donors responded to LPS stimulation and produced significant levels of IL-1β, IL-6, and TNF-α across individual donors. C-2250 produced dose-dependent inhibition of IL-1β, IL-6, and TNF-α cytokines.
[0102] Example 2 Human CD19-specific CAR-T effector cells from donors were co-cultured with Raji, a target B cell line expressing human CD19, at various effector-to-target cell ratios of 5:1, 10:1, and 20:1 in the presence of C-2250. After 6 or 24 hours of co-culture at 37°C with 5% CO2, cells were harvested for CAR-T-mediated target cell lysis or tissue culture supernatants were harvested for cytokine analysis. C-2250 was used at concentrations of 500 μM, 1000 μM, and 1500 μM and pre-incubated with CAR-T cells before the addition of tumor target cells.
[0103] 2A-C show the results of a CD19 CAR-T co-culture assay with CD-19 tumor cells (Raji) at 6 hours, showing CAR-T-mediated tumor targeting in the presence of increasing concentrations of C-2250 (E:T ratios of 5:1, 10:1, and 20:1 shown in FIG. 2A, FIG. 2B, and FIG. 2C, respectively). FIG. 3A-C show the results of a CD19 CAR-T co-culture assay with CD-19 tumor cells (Raji) at 24 hours, showing CAR-T-mediated tumor targeting in the presence of increasing concentrations of C-2250 (E:T ratios of 5:1, 10:1, and 20:1 shown in FIG. 3A, FIG. 3B, and FIG. 3C, respectively).
[0104] Figure 4 shows that C-2250 reduces IL-2 cytokine release mediated by CD19 CAR-T cells across a range of effector to target ratios. Figure 5 shows that C-2250 reduces TNF-α cytokine release mediated by CD19 CAR-T cells across a range of effector to target ratios. Figure 6 shows that C-2250 reduces IFN-γ cytokine release mediated by CD19 CAR-T cells across a range of effector to target ratios.
[0105] C-2250 inhibited CD19 CAR-T-mediated CD19 expression at various effector-to-target cell ratios for 6 or 24 hours. + It does not inhibit cytotoxicity to tumor target cells. C-2250 shuts down cytokine release, including IL-1β, IL-6, TNF-α, and IFN-γ cytokines.
[0106] Example 3 Inhibition of cytokine release by C-2250 in the presence of a bispecific CD19 T cell inducer was assessed. Human PBMCs from 10 donors were co-cultured with Ramos cells (a B cell line expressing human CD19) in the presence of the T cell bispecific therapy Blintumomab (BLINCYTO™) and C-2250 was added. BLINCYTO™ was used at a fixed concentration of 100 ng / ml, known to be functionally active in this co-culture system, to inhibit T cell-mediated CD19 + It induced cytotoxicity and cytokine release responses in target cells (Ramos).
[0107] Co-culture was performed for 24 hours at 37°C with 5% CO2, after which cell or tissue culture supernatants were harvested for analysis. C-2250 was used at concentrations of 500 μM, 1000 μM, and 1500 μM and pre-incubated with T cells prior to the addition of BLINCYTO™.
[0108] FIG. 7 shows that BLINCYTO™ enhanced target cell cytotoxicity in Ramos cells from all donors tested.
[0109] FIG. 8 shows that C-2250 inhibits BLINCYTO™-mediated CD19 + This indicates that the cytotoxicity to tumor target cells was not reduced.
[0110] Figure 9A shows the effect of BLINCYTO™ on IL-1β cytokine release in the donors tested. Figure 9B shows that C-2250 reduced BLINCYTO™ T cell-mediated IL-1β cytokine release in the donors tested.
[0111] Figure 10A shows the effect of BLINCYTO™ on IL-2 cytokine release in the donors tested. Figure 10B shows that C-2250 reduced BLINCYTO™ T cell-mediated IL-2 cytokine release in the donors tested.
[0112] Figure 11A shows the effect of BLINCYTO™ on IL-6 cytokine release in the donors tested. Figure 11B shows that C-2250 reduced BLINCYTO™ T cell-mediated IL-6 cytokine release in the donors tested.
[0113] Figure 12A shows the effect of BLINCYTO™ on TNF-α cytokine release in the donors tested. Figure 12B shows that C-2250 reduced BLINCYTO™ T cell-mediated TNF-α cytokine release in the donors tested.
[0114] Figure 13A shows the effect of BLINCYTO™ on IFN-γ cytokine release in the donors tested. Figure 13B shows that C-2250 reduced BLINCYTO™ T cell-mediated IFN-γ cytokine release in the donors tested.
[0115] These results suggest that C-2250 surprisingly inhibits BLINCYTO™-mediated CD19 + It was demonstrated that it did not reduce the degree of cytotoxicity towards tumor target cells, but did reduce the release of all cytokines tested.
[0116] FIG. 14 shows that C-2250 enhanced tumor target cytotoxicity in the absence of BLINCYTO™.
[0117] Although the subject matter of the present disclosure has been described and illustrated in some detail with reference to several illustrative examples, including various combinations and subcombinations of features, those skilled in the art will readily appreciate that other aspects and variations and modifications thereof are encompassed within the scope of the present disclosure. Moreover, the description of such aspects, combinations and subcombinations is not intended to imply that the claimed subject matter requires features or combinations of features other than those expressly recited in the claims. Accordingly, the scope of the present disclosure is intended to include all modifications and variations encompassed within the spirit and scope of the appended claims.
Claims
1. A pharmaceutical for treating cytokine release syndrome (CRS) or a disease characterized by a cytokine storm in a subject in need of such treatment, said pharmaceutical comprising compound 2250, a pharma- ceutically acceptable salt, hydrate, or solvate thereof. 【Chemistry 1】
2. The pharmaceutical product of claim 1 , wherein the subject has undergone, is undergoing, or will undergo T cell induction therapy.
3. 2. The pharmaceutical product of claim 1, wherein the subject has received, is receiving, or will receive chimeric antigen receptor expressing T cell (CAR T cell) therapy, antibody therapy, or bispecific antibody therapy.
4. 2. The pharmaceutical product of claim 1, wherein the pharmaceutical product is administered prior to, concurrently with, or following CAR T cell therapy, antibody therapy, or bispecific antibody therapy.
5. The medicament of any one of claims 1 to 3, wherein the medicament is administered 12 hours to 96 hours prior to the initiation of CAR T cell therapy or bispecific antibody therapy.
6. A pharmaceutical product described in any one of claims 1 to 5, wherein the pharmaceutical product is administered within 24 hours of onset of fever as a clinical sign of impending CRS or cytokine storm in a subject receiving T cell induction therapy.
7. A pharmaceutical agent described in any one of claims 1 to 6, wherein the pharmaceutical agent is administered within 24 hours of detection of one or more biomarkers indicative of impending CRS or cytokine storm in a subject receiving T cell induction therapy.
8. 8. The pharmaceutical product of claim 7, wherein the one or more biomarkers indicative of impending CRS are increased serum, blood, or tissue levels of one or more of IL-1β, IL-1RA, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IP-10, IFN-α, IFN-γ, G-CSF, and TNF-α.
9. The method of any one of claims 1 to 8, wherein the medicament is administered at least every other week for between 4 and 8 weeks.
10. 10. The pharmaceutical product of any one of claims 1 to 9, wherein administration of the pharmaceutical product does not reduce the efficacy of CAR T cell therapy, antibody therapy, or bispecific antibody therapy.
11. The pharmaceutical product of any one of claims 1 to 10 for reducing neurotoxicity in a subject in need of CAR T cell therapy, antibody therapy, or bispecific antibody therapy.
12. The pharmaceutical product of any one of claims 1 to 11, wherein the cause of the cytokine release syndrome or cytokine storm comprises an infectious stimulus, an infectious pathology, or an infectious syndrome, or the cause of the cytokine release syndrome or cytokine storm comprises a non-infectious stimulus, a non-infectious pathology, or a non-infectious syndrome, or any combination thereof.
13. The infectious stimulus, infectious condition, or infectious syndrome comprises influenza, avian influenza, severe acute respiratory syndrome (SARS), Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (HLH), sepsis, gram-negative sepsis, malaria, Ebola virus infection, smallpox virus infection, systemic gram-negative bacterial infection, or Jarisch-Herxheimer syndrome, or the non-infectious ... The inflammatory syndromes include hemophagocytic lymphohistiocytosis (HLH), sporadic HLH, macrophage activation syndrome (MAS), chronic arthritis, systemic juvenile idiopathic arthritis (sJIA), Still's disease, cryopyrin-associated periodic syndromes (CAPS), familial cold autoinflammatory syndrome (FCAS), familial cold urticaria (FCU), Muckle-Wells syndrome (MWS), chronic infantile neurocutaneous arthropathy (CINCA) syndrome, inherited or degenerated genes in the NLRP3 gene,Cryopyrinosis, including novo gain-of-function mutations, inherited autoinflammatory disorders, acute pancreatitis, severe burns, trauma, acute respiratory distress syndrome, immunotherapy, monoclonal antibody therapy, secondary to drug use, secondary to inhalation of toxins, lipopolysaccharide (LPS), gram-positive toxins, fungal toxins, glycosylphosphatidylinositol (GPI), modulation of RIG-1 gene expression, appendicitis, peptic, gastric, and duodenal ulcers, peritonitis, pancreatitis, ulcerative colitis, pseudomembranous colitis, acute and ischemic colitis, diverticulitis, epiglottitis, achalasia, cholangitis, Cholecystitis, hepatitis, Crohn's disease, enteritis, Whipple's disease, asthma, allergy, anaphylactic shock, immune complex disease, organ ischemia, reperfusion injury, organ necrosis, hay fever, sepsis, toxemia, endotoxic shock, cachexia, hyperthermia, eosinophilic granuloma, granulomatosis, sarcoidosis, septic abortion, epididymitis, vaginitis, prostatitis, urethritis, bronchitis, emphysema, rhinitis, cystic fibrosis, interstitial pneumonia, alveolitis, bronchiolitis, pharyngitis, pleurisy, sinusitis, parasitic infection, bacterial infection, viral infection, autoimmune disease, influenza, respiratory syncytial virus infection, herpes simplex, pes infection, HIV infection, hepatitis B virus infection, hepatitis C virus infection, disseminated bacteremia, dengue fever, candidiasis, malaria, filariasis, amebiasis, hydatid cyst, burn, dermatitis, dermatomyositis, sunburn, urticaria, warts, wheals, vasculitis, vasculitis, endocarditis, arteritis, atherosclerosis, thrombophlebitis, pericarditis, myocarditis, myocardial ischemia, periarteritis nodosa, rheumatic fever, celiac disease, congestive heart failure, adult respiratory distress syndrome, coronavirus, SARS-CoV-2, Middle East Respiratory Syndrome (MERS), multisystem inflammatory syndrome, corona virus 13. The pharmaceutical product of claim 12, comprising an inflammatory disease caused by rheumatoid arthritis, inflammatory bowel syndrome, Kawasaki disease, meningitis, encephalitis, cerebral infarction, cerebral embolism, Guillain-Barré syndrome, neuritis, neuralgia, spinal cord injury, paralysis, uveitis, arthritis, arthralgia, osteomyelitis, neuromyelitis optica spectrum disorder (NMSOD), fasciitis, Paget's disease, gout, periodontal disease, rheumatoid arthritis, synovitis, myasthenia gravis, thyroiditis, systemic lupus erythematosus, Goodpasture's syndrome, Behcet's syndrome, allograft rejection, graft versus host disease, ankylosing spondylitis, Berger's disease, Reiter's syndrome, or Hodgkin's disease.
14. Use of compound 2250, a pharma- ceutically acceptable salt, hydrate, or solvate thereof in the manufacture of a medicament for treating cytokine release syndrome (CRS) or a disease characterized by a cytokine storm in a subject in need of such treatment. 【Chemistry 2】
15. 15. The use of claim 14, wherein the subject has undergone, is undergoing, or will undergo T cell induction therapy.
16. 15. The use of claim 14, wherein the subject has received, is receiving, or will receive chimeric antigen receptor expressing T cell (CAR T cell) therapy, antibody therapy, or bispecific antibody therapy.
17. 15. The use of claim 14, wherein the medicament is administered prior to, simultaneously with, or after CAR T cell therapy, antibody therapy, or bispecific antibody therapy.
18. 18. The use according to any one of claims 14 to 17, wherein the medicament is administered 12 hours to 96 hours prior to the initiation of CAR T cell therapy or bispecific antibody therapy.
19. The use described in any one of claims 14 to 18, wherein the pharmaceutical agent is administered within 24 hours of onset of fever as a clinical sign of impending CRS or cytokine storm in a subject receiving T cell induction therapy.
20. The use of any one of claims 1 to 6, wherein the pharmaceutical agent is administered within 24 hours of detection of one or more biomarkers indicative of impending CRS or cytokine storm in a subject receiving T cell induction therapy.
21. 21. The use of claim 20, wherein the one or more biomarkers indicative of impending CRS are increased serum, blood or tissue levels of one or more of IL-1β, IL-1RA, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IP-10, IFN-α, IFN-γ, G-CSF, and TNF-α.
22. The use according to any one of claims 14 to 21, wherein the medicament is administered at least every other week for between 4 and 8 weeks.
23. 23. The use according to any one of claims 14 to 22, wherein administration of the medicament does not reduce the efficacy of CAR T cell therapy, antibody therapy, or bispecific antibody therapy.
24. The use according to any one of claims 14 to 23, wherein the medicament is for the reduction of neurotoxicity in a subject in need of CAR T cell therapy, antibody therapy, or bispecific antibody therapy.
25. 25. The use according to any one of claims 14 to 24, wherein the cause of the cytokine release syndrome or cytokine storm comprises an infectious stimulus, an infectious pathology or an infectious syndrome, or the cause of the cytokine release syndrome or cytokine storm comprises a non-infectious stimulus, a non-infectious pathology or a non-infectious syndrome, or any combination thereof.
26. The infectious stimulus, infectious condition, or infectious syndrome comprises influenza, avian influenza, severe acute respiratory syndrome (SARS), Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (HLH), sepsis, gram-negative sepsis, malaria, Ebola virus infection, smallpox virus infection, systemic gram-negative bacterial infection, or Jarisch-Herxheimer syndrome, or the non-infectious ... The inflammatory syndromes include hemophagocytic lymphohistiocytosis (HLH), sporadic HLH, macrophage activation syndrome (MAS), chronic arthritis, systemic juvenile idiopathic arthritis (sJIA), Still's disease, cryopyrin-associated periodic syndromes (CAPS), familial cold autoinflammatory syndrome (FCAS), familial cold urticaria (FCU), Muckle-Wells syndrome (MWS), chronic infantile neurocutaneous arthropathy (CINCA) syndrome, inherited or degenerated genes in the NLRP3 gene,Cryopyrinosis, including novo gain-of-function mutations, inherited autoinflammatory disorders, acute pancreatitis, severe burns, trauma, acute respiratory distress syndrome, immunotherapy, monoclonal antibody therapy, secondary to drug use, secondary to inhalation of toxins, lipopolysaccharide (LPS), gram-positive toxins, fungal toxins, glycosylphosphatidylinositol (GPI), modulation of RIG-1 gene expression, appendicitis, peptic, gastric, and duodenal ulcers, peritonitis, pancreatitis, ulcerative colitis, pseudomembranous colitis, acute and ischemic colitis, diverticulitis, epiglottitis, achalasia, cholangitis, Cholecystitis, hepatitis, Crohn's disease, enteritis, Whipple's disease, asthma, allergy, anaphylactic shock, immune complex disease, organ ischemia, reperfusion injury, organ necrosis, hay fever, sepsis, toxemia, endotoxic shock, cachexia, hyperthermia, eosinophilic granuloma, granulomatosis, sarcoidosis, septic abortion, epididymitis, vaginitis, prostatitis, urethritis, bronchitis, emphysema, rhinitis, cystic fibrosis, interstitial pneumonia, alveolitis, bronchiolitis, pharyngitis, pleurisy, sinusitis, parasitic infection, bacterial infection, viral infection, autoimmune disease, influenza, respiratory syncytial virus infection, herpes simplex, pes infection, HIV infection, hepatitis B virus infection, hepatitis C virus infection, disseminated bacteremia, dengue fever, candidiasis, malaria, filariasis, amebiasis, hydatid cyst, burn, dermatitis, dermatomyositis, sunburn, urticaria, warts, wheals, vasculitis, vasculitis, endocarditis, arteritis, atherosclerosis, thrombophlebitis, pericarditis, myocarditis, myocardial ischemia, periarteritis nodosa, rheumatic fever, celiac disease, congestive heart failure, adult respiratory distress syndrome, coronavirus, SARS-CoV-2, Middle East Respiratory Syndrome (MERS), multisystem inflammatory syndrome, corona 26. The use of claim 25, including the following conditions: viral-induced inflammatory syndrome, Kawasaki disease, meningitis, encephalitis, cerebral infarction, cerebral embolism, Guillain-Barré syndrome, neuritis, neuralgia, spinal cord injury, paralysis, uveitis, arthritis, arthralgia, osteomyelitis, neuromyelitis optica spectrum disorder (NMSOD), fasciitis, Paget's disease, gout, periodontal disease, rheumatoid arthritis, synovitis, myasthenia gravis, thyroiditis, systemic lupus erythematosus, Goodpasture's syndrome, Behcet's syndrome, allograft rejection, graft versus host disease, ankylosing spondylitis, Berger's disease, Reiter's syndrome, or Hodgkin's disease.
Citation Information
Patent Citations
Methods of making oxathiazine-like compounds
JP2018502909A
Treatment for triple-negative breast cancer
JP2019508476A
Oxathiazine derivatives as antibacterial and anticancer agents
WO2013190355A1
